Alexander Cumbo has sold stock and made no open-market buys since Jul 2017

Alexander (Bo) Cumbo is the President and Chief Executive Officer of Solid Biosciences Inc. (SLDB), a gene therapy company, a position he has held since December 2022 with a tenure of approximately 3.2 years as of early 2026( In this role, he leads the company, earning total yearly compensation of $4.87 million (12.5% salary, 87.5% bonuses including stock and options) and directly owning 0.35% of shares worth about $1.77 million( Recently, as a corporate insider, he executed automatic sales of shares to cover tax withholding on vested restricted and performance stock units, including 80,258 shares on February 2, 2026, at $6.4369 per share, and 48,913 shares on February 4, 2026, at $6.4419 per share, retaining 222,018 shares post-transaction(

Cumbo brings extensive biotech experience, having served as the founding CEO of AavantiBio (backed by Bain, Perceptive, and RA Capital) and nearly eight years as Executive Vice President and Chief Commercial Officer at Sarepta Therapeutics, where he launched multiple rare disease therapies and built global commercial operations( He holds a B.S. in Laboratory Technology from Auburn University and currently serves on the boards of Vor Biopharma (joined July 16, 2025), Verve Therapeutics, and Climb Bio, adding expertise in commercialization, company building, and gene therapy scaling(

Written by Perplexity from public sources.